

Index

A

AES. *See* Auger electron spectroscopy (AES)

AFM. *See* Atomic force microscopy (AFM)

Amorphous calcium phosphate (ACP)

advantages, 181

CPP complex, 182–183

morphology, 181

PEO, 182

stabilizers

comprehensive analysis, 183

enamel lesions, 184

GTR, 184

Pchi and CMC, 184–186

phosphorus-based analogue, 184

PILP, 183–184

SEM and EDX results, 186–188

TEM results, 188

transition phase, 186, 187

Antibacterial nanoparticles

antibiotic-resistant bugs, 97–98

antimicrobials

clinical outcomes, 102

EDTA, 102

histological sections, 103

limitations, 103

microcomputed tomography, 103

requirements, 102–103

therapeutic strategy, 102–103

bacterial biofilms

definition, 99

endodontic biofilms, 101–102

EPS matrix, 100–101

microcolonies, 99–100

seed dispersal, 100

water channels, 99

BAG, 107

biofunctionalization, 111–112

composition, 104

CS NPs

carboxy-methylated chitosan, 104

chemical modifications and grafting, 104

degree of deacetylation, 107

physical characteristics, 104

positive and negative charged membrane,
104, 106–107

structures, 104

ZnO NP, 107–108

factors, 97–98

fluorescent labeling, 98–99

heavy metal ions, 99

literatures, 104–105

metallic nanoparticles, 99

PDT, 113–114

root canal sealers

properties, 109

QAPEI, 110–111

ZnO NPs, 109–110

silver nanoparticles

application, 108

cytotoxicity, 108–109

potential browning/blackening, 109

prevention, 107–108

Atomic force microscopy (AFM), 32–34

Auger electron spectroscopy (AES), 32–33

B

Beta tricalcium phosphate (β -TCP), 179–180

Bioactive glass (BAG), 107, 111

Bioglass, 6, 10–11

C

Calcium-deficient hydroxyapatite (CDHA), 143

Calcium fluoride nanoparticles ($n\text{CaF}_2$), 155

Cancer chemotherapy

liposomal delivery system

clinical phase, 77

doxil, 75–77

pre-clinical phase, 77

polymeric nanomicelles

clinical candidates, 77–78

CMC, 77–78

hydrolyzable polyesters, 80

- Cancer chemotherapy (*cont.*)
- hydrophobic drugs, 80–81
 - NC-6004, 79–80
 - NK105, 78–79
 - NK911, 80
 - PEG and PLA lengths, 80
 - sizes, 77
 - triblocks, diblocks and four-armed blocks, 77
- RES, 75
- solid nanoparticles
- active targeting, 82–83
 - advantages, 81
 - blood lifetimes, 83–84
 - copolymers, 81
 - core–shell particles, 81
 - passive targeting, 81–82
 - PLGA nanoparticles, 81
 - stability issues, 83
 - targeting molecules, 74–75
- Casein phosphopeptides (CPP) complex, 182–183
- CeO₂-stabilized tetragonal zirconia polycrystal (Ce-TZP), 160
- Chitosan nanoparticles (CS NPs)
- carboxy-methylated chitosan, 104
 - chemical modifications and grafting, 104
 - degree of deacetylation, 107
 - physical characteristics, 104
 - positive and negative charged membrane, 104, 106–107
 - structures, 104
 - ZnO NP, 107–108
- Chlorhexidine-hexametaphosphate (CHX-HMP), 143–144
- Cisplatin (NC-6004), 79–80
- Colloidal platinum nanoparticles (CPN), 152
- Critical micellar concentration (CMC)
- nanoliposomal carriers, 83
 - Pchi, 184–186
 - polymeric nanomicelles, 73, 77–78
- D**
- Dental restoration
- antimicrobial silver, 14–15
 - bioactive glass, 10–11
 - dental deformities, 17
 - dentin, 17
 - enamel layer, 8
 - HAP, 8–10
 - nanocrystalline HA, 8
 - periodontal diseases, 17–18
 - signaling molecules, 17, 19
 - synthetic silicates, 15–16
 - titanium implants, 10–13
 - tooth development, 6–7
 - zirconia, 13–14
- Dentin
- biological composites, 122
 - bonding systems
 - adhesive hybrid layer, 149–150
 - CPN, 152
 - fixer layer, 148–149
 - mechanical properties, 153
 - nACP, 149–150
 - nanogels, 153
 - outcomes, 149
 - PMAA-g-nanoclay, 152–153
 - QADM, 150–151
 - synthesized HA nanorods, 151–152
 - zirconia, 152
 - Zn-doped adhesives, 152
 - chemical cross-linking, 126–127
 - chitosan nanoparticles, 128
 - CSnp incorporation, 129, 130
 - CSRBNps, 128–129
 - effects
 - bonding, 133–134
 - chemical stability, 130–131
 - mechanical properties, 130
 - MMPs, 131–133
 - enamel matrix, 17
 - fiber-reinforced composite, 122–123
 - iatrogenic factors, 125–126
 - mechanical stability, 123–124
 - non-iatrogenic factors, 124–125
 - PDT, 127–128
 - physical cross-linking, 126–127
 - proteoglycans and glycosaminoglycans, 123
 - restoration, 17
 - root-filled teeth, 122
 - structural integrity, 124
 - type I collagen, 123
 - VRF, 121–122
 - water content, 124
- Derjaguin, Landau, Verwey and Overbeek (DLVO) theory, 49
- Distearoyl-phosphatidyl-ethanolamine (DSPE), 75–76
- Doxorubicin (NK911), 80
- E**
- Easy-quick-unique-intelligent-aesthetic (EQUIA), 145–146
- Electron spectroscopy for chemical analysis (ESCA), 29
- Emmett–Teller (BET) gas absorption/desorption method, 59
- Energy-dispersive X-ray spectroscopy, 186–188
- Ethylenediaminetetraacetic acid (EDTA), 102, 125
- Extracellular polymeric substance (EPS) matrix, 100–101
- F**
- Fluorescein isothiocyanate (FITC), 112
- Fourier transform infrared spectroscopy (FTIR), 32
- G**
- Glass ionomer cement (GIC) fillers
- experimental materials
 - advantages, 142
 - aluminum fluoride, 142

- CDHA, 143
 - CHX-HMP, 143–144
 - disadvantages, 142
 - hydroxyapatite, 142–143
 - titanium dioxide, 143
 - HEMA, 142
 - Ketac Nano (3M ESPE)
 - clinical performance, 144–145
 - EQUIA, 145–146
 - fluoride release, 144
 - nanoclusters, 144
 - nano-filled surface varnish, 145–146
 - public health systems, 146
 - SEM micrographs, 144–145
 - tensile stress, 142
 - Guided tissue remineralization (GTR), 175, 184
- H**
- Halloysite nanotubes (HNTs), 156
 - HAP. *See* Hydroxyapatite (HAP)
 - High-content screening (HCS), 64–65
 - High-resolution magic angle spinning nuclear magnetic resonance spectroscopy (HRMAS NMR), 36
 - High-resolution transmission electron microscopy (HRTEM), 56, 59
 - High-throughput screening (HTS), 63
 - Hydroxyapatite (HAP)
 - CDHA, 143
 - dental restoration, 8–10
 - nanoparticles, 178, 180–181
 - 2-hydroxyethyl methacrylate (HEMA), 142, 144, 146
- I**
- Inductively coupled plasma mass spectroscopy (ICP-MS), 40, 59
- L**
- Luting systems
 - application, 156–157
 - biomimetic approach, 156
 - cement type, 159
 - clinical performance, 158–159
 - Filtek Supreme Standard, 157
 - Filtek Supreme Translucent, 157
 - glyoxylic acid, 156
 - HNTs, 156
 - nACP, 154
 - nanohybrid composite, 158
 - nCaF₂, 155
 - nDCPA, 155–156
 - nZnO, 155
 - ormosils, 157
 - QADM, 154–155
 - QA-PEI, 154
 - sealants, 159
 - silver, 155
 - sol-gel method, 153
 - water sorption, 147, 158
- M**
- Matrix metalloproteinases (MMPs), 131–133
 - 3-methacryloxypropyl trimethoxy silane (MPTMS), 146
 - Minimally invasive dentistry (MID)
 - biomimetic mineralization, 175
 - components, 174
 - dental hard tissue and caries, 176–177
 - evidence-based approach, 174
 - fluoride treatment, 175
 - nanomaterials, 175
 - organic matrix, 175
 - remineralization
 - ACP (*see* Amorphous calcium phosphate (ACP))
 - β-TCP, 179–180
 - calcium fluoride, 179
 - caries development, 177–178
 - clinical methodology, 178
 - dentin hypersensitivity, 178
 - emerging view, 178
 - Gibbs free energy change, 178
 - HAP, 178, 180–181
 - principles, 177
- N**
- nACP. *See* Nanoparticles of amorphous calcium phosphate (nACP)
 - Nano-dicalcium phosphate anhydrous (nDCPA), 155–156
 - Nanomaterials
 - agglomeration behaviour, 48–49
 - bioglass, 6, 10–11
 - dispersion, 49–50
 - fibre pathogenicity paradigm, 51–52
 - medicine, 45–47
 - one-dimensional nanostructures (*see* Nanoparticles)
 - physico-chemical properties, 57
 - safety testing
 - cytotoxicity testing, 59–60
 - cytotoxic responses, 62–63
 - hierarchical oxidative stress paradigm, 60–61
 - inflammatory responses, 62
 - nanomaterial-mediated toxicity, 60
 - in vitro* cellular toxicity, 60
 - in vitro* nanotoxicity testing, 58–59
 - in vivo* testing, 57–58
 - shapes, 50–51
 - sizes, 47–48
 - surface functionality, 52–53
 - toxicity
 - screening methods, 63–65
 - silicates, 55
 - silver, 55–56
 - zinc oxide, 54
 - two-dimensional nanostructures, 24
 - zero-dimensional nanostructures, 24
 - Nanomedicine
 - anti-sense therapy, 92
 - catheter-based drug delivery, 92
 - clinical applications (*see* Cancer chemotherapy)

- Nanomedicine (*cont.*)
- dendrimers, 74–75
 - endodontic infection, 85–86
 - liposomes, 72, 74
 - ocular applications, 85
 - periodontitis (*see* Periodontitis)
 - polymeric nanomicelles, 73–74
 - polymeric nanoparticles, 73
 - prognosis, 92
- Nanoparticles
- antibacterial (*see* Antibacterial nanoparticles)
 - cellular uptake, 38–40
 - CS NPs (*see* Chitosan nanoparticles (CS NPs))
 - cytotoxicity assay, 40–41
 - drug delivery system (*see* Nanomedicine)
 - protein adsorption, 36–38
 - RES, 25
 - restorative materials (*see* Restorative materials)
 - size, 25–27
 - surface charge
 - dimensionless product, 28
 - electrophoretic mobility, 28
 - liquid layer, 27
 - proteins and cell membrane interaction, 26–27
 - zeta potential, 27–29
 - surface composition
 - AES, 32–33
 - AFM, 32–34
 - C-C/C-H peak, 30–31
 - COOH peak, 30–31
 - FTIR, 32, 35
 - FT-IR spectra, 32, 35
 - HPG, 29–30
 - HRMAS NMR, 36
 - MPS-modified magnetic nanoparticles, 29–30
 - MTX, 32, 35
 - NMR, 36
 - PAN, 35
 - superparamagnetic iron oxide nanoparticles, 29
 - XPS, 29–31
- Nanoparticles of amorphous calcium phosphate (nACP), 149–150, 154
- Nano-zinc oxide (nZnO)
- CS NP, 107–108
 - luting systems, 155
 - root canal sealers, 109–110
- National Nanotechnology Initiative (NNI), 47
- Nuclear magnetic resonance (NMR), 36
- P**
- Paclitaxel (NK105), 78–79
- Periodontitis
- bacterial biofilms, 87
 - electrospun nanofibres, 87
 - localized delivery, 86–87
 - microparticles
 - calcium hydroxide, 88
 - charged nanoparticles, 90–91
 - doxycycline, 88
 - encapsulation techniques, 87–88
 - nano-based delivery systems, 91–92
 - periodontal pockets and root canals, 87
 - polymeric nanoparticles, 88–90
 - spray-drying, 88
 - surface-charged nanoparticles, 90–91
 - targeting nanoparticles, 91
 - root canal disinfection and stabilization, 2–3
 - tooth loose/loss, 85–86
- Phosphatidylinositol (PI), 91
- Phosphorylated chitosan (Pchi), 184–186
- Photodynamic therapy (PDT)
- antimicrobial efficacy, 113–114
 - photosensitizers, 127–128
 - selective eradication, 90–91
- Photosensitizers (PSs), 90–91
- PILP. *See* Polymer-induced liquid precursor (PILP)
- Poly(D,L-lactic acid and Glycolic acid copolymer (PLGA)), 72, 81–82
- Poly(ethylene glycol) (PEG), 71, 73, 80
- Polyacrylonitrile (PAN), 35
- Polyalkenoate cements. *See* Glass ionomer cement (GIC) fillers
- Polyethylene oxide (PEO), 182
- Poly(methacrylic acid)-grafted-nanoclay (PMAA-g-nanoclay), 152–153
- Poly L-lactide (PLA), 71, 73, 80
- Polymer-induced liquid precursor (PILP), 183–184
- Q**
- Quaternary ammonium dimethacrylate (QADM), 150–151, 154–155
- Quaternary ammonium polyethylenimine (QAPEI), 110–111, 154
- R**
- Restorative materials
- ceramic materials, 163
 - GIC fillers (*see* Glass ionomer cement (GIC) fillers)
 - hydroxyapatite, 163
 - indirect restoration
 - Ce-TZP, 160
 - diatomite, 160
 - Lava Ultimate, 162
 - NanoZr, 161
 - tensile stress, 161
 - thermal expansion, 161–162
 - veneer-coping interface, 159–161
 - Y-TZP, 160–161
 - resin-based materials
 - application, 148
 - dentine bonding systems (*see* Dentin, bonding systems)
 - etch-and-rinse techniques, 148
 - luting systems (*see* Luting systems)
 - MPTMS, 146
 - nanofillers, 146–148
 - nanohybrids, 146

posterior class I/II restoration, 148
self-etch techniques, 148
tooth structure and restoration, 148
water sorption and discoloration, 162–163
Reticuloendothelial system (RES), 25, 75
Rose Bengal–conjugated chitosan nanoparticles
(CSRBnps), 128–129

S

Scanning electron microscopy (SEM), 59, 144–145,
186–188
Scanning tunneling microscopy (STM), 32

T

Thermogravimetric analysis (TGA), 59
Time-of-flight secondary-ion mass spectrometry
(TOF-SIMS), 32
Titanium implants, 10–13
Transmission electron microscopy (TEM), 13,
26–27, 59, 188

V

Vertical root fracture (VRF), 121–122

X

X-ray photoelectron spectroscopy (XPS), 29,
31–32, 59

Y

Yttria–tetragonal zirconia polycrystal (Y-TZP), 13–14,
160–161

Z

Zirconia
bonding systems, 152
dental adhesives, 13–14
mechanical properties, 13
Y-TZP, 13–14